Aviva PLC Gilead Sciences, Inc. Transaction History

Aviva PLC

$36.8 Billion
Q3 2024

A detailed history of Aviva PLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Aviva PLC holds 1,148,632 shares of GILD stock, worth $103 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares

1,148,632

Previous 1,146,324 0.2%

Holding current value

$103 Million

Previous $78.6 Million 22.41%

% of portfolio

0.26%

Previous 0.23%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$66.59 - $83.99 $153,689 - $193,848	2,308 Added 0.2%	1,148,632 $96.3 Million
Q2 2024 Aug 02, 2024	BUY	$63.15 - $72.88 $15.2 Million - $17.5 Million	240,384 Added 26.53%	1,146,324 $78.6 Million
Q1 2024 May 14, 2024	BUY	$71.58 - $87.29 $2.82 Million - $3.44 Million	39,455 Added 4.55%	905,940 $66.4 Million
Q4 2023 Feb 09, 2024	BUY	$73.27 - $83.09 $4.85 Million - $5.5 Million	66,226 Added 8.28%	866,485 $70.2 Million
Q3 2023 Nov 13, 2023	BUY	$73.94 - $80.67 $966,691 - $1.05 Million	13,074 Added 1.66%	800,259 $60 Million
Q2 2023 Aug 10, 2023	BUY	$76.01 - $86.7 $5.2 Million - $5.93 Million	68,380 Added 9.51%	787,185 $60.7 Million
Q1 2023 May 12, 2023	BUY	$77.31 - $88.08 $7.38 Million - $8.41 Million	95,443 Added 15.31%	718,805 $59.6 Million
Q4 2022 Feb 09, 2023	BUY	$62.32 - $89.47 $6.55 Million - $9.41 Million	105,121 Added 20.28%	623,362 $53.5 Million
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $1.16 Million - $1.33 Million	-19,547 Reduced 3.63%	518,241 $32 Million
Q2 2022 Aug 04, 2022	BUY	$57.72 - $65.01 $6.77 Million - $7.63 Million	117,295 Added 27.89%	537,788 $33.2 Million
Q1 2022 May 13, 2022	BUY	$57.92 - $72.58 $1.12 Million - $1.41 Million	19,418 Added 4.84%	420,493 $25 Million
Q4 2021 Feb 10, 2022	SELL	$64.88 - $73.64 $3.52 Million - $3.99 Million	-54,237 Reduced 11.91%	401,075 $29.1 Million
Q3 2021 Nov 12, 2021	BUY	$67.69 - $73.03 $571,777 - $616,884	8,447 Added 1.89%	455,312 $31.8 Million
Q2 2021 Aug 10, 2021	BUY	$63.47 - $69.35 $1.75 Million - $1.92 Million	27,639 Added 6.59%	446,865 $30.8 Million
Q1 2021 May 13, 2021	SELL	$60.0 - $68.46 $22,980 - $26,220	-383 Reduced 0.09%	419,226 $27.1 Million
Q4 2020 Feb 10, 2021	BUY	$56.65 - $64.55 $794,572 - $905,378	14,026 Added 3.46%	419,609 $24.4 Million
Q3 2020 Nov 12, 2020	SELL	$62.1 - $78.08 $878,156 - $1.1 Million	-14,141 Reduced 3.37%	405,583 $25.6 Million
Q2 2020 Aug 13, 2020	SELL	$72.34 - $84.0 $2.09 Million - $2.43 Million	-28,878 Reduced 6.44%	419,724 $32.3 Million
Q1 2020 May 14, 2020	BUY	$62.63 - $80.22 $16,910 - $21,659	270 Added 0.06%	448,602 $33.5 Million
Q4 2019 Feb 10, 2020	SELL	$61.62 - $67.78 $145,484 - $160,028	-2,361 Reduced 0.52%	448,332 $29.1 Million
Q3 2019 Nov 12, 2019	SELL	$62.51 - $69.0 $8.37 Million - $9.24 Million	-133,845 Reduced 22.9%	450,693 $28.6 Million
Q2 2019 Jul 30, 2019	SELL	$61.87 - $69.38 $752,401 - $843,730	-12,161 Reduced 2.04%	584,538 $39.5 Million
Q1 2019 May 14, 2019	SELL	$62.53 - $70.05 $339,100 - $379,881	-5,423 Reduced 0.9%	596,699 $38.8 Million
Q4 2018 Feb 12, 2019	SELL	$60.54 - $79.0 $8.36 Million - $10.9 Million	-138,139 Reduced 18.66%	602,122 $37.7 Million
Q3 2018 Nov 13, 2018	SELL	$71.28 - $78.92 $1.87 Million - $2.07 Million	-26,254 Reduced 3.43%	740,261 $57.2 Million
Q2 2018 Aug 01, 2018	SELL	$64.88 - $75.68 $694,540 - $810,154	-10,705 Reduced 1.38%	766,515 $54.3 Million
Q1 2018 May 14, 2018	SELL	$72.84 - $88.8 $4.55 Million - $5.55 Million	-62,528 Reduced 7.45%	777,220 $58.6 Million
Q4 2017 Feb 13, 2018	SELL	$71.15 - $83.52 $7.47 Million - $8.77 Million	-104,966 Reduced 11.11%	839,748 $60.2 Million
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $926,613 - $1.1 Million	12,850 Added 1.38%	944,714 $76.5 Million
Q2 2017 Aug 07, 2017	BUY	N/A	931,864	931,864 $66 Million

Others Institutions Holding GILD

# of Institutions

1,931

Shares Held

991M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

News

Stay updated on Aviva PLC with notifications on news.

Account